Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,333,097 | $808,980 | $1,052,294 | $1,134,157 |
| - Cash | $116,808 | $108,636 | $153,993 | $154,083 |
| + Debt | $345,431 | $1,675 | $345,630 | $345,739 |
| Enterprise Value | $1,561,720 | $702,019 | $1,243,931 | $1,325,813 |
| Revenue | $45,871 | $37,958 | $20,042 | $7,680 |
| % Growth | 20.8% | 89.4% | 161% | – |
| Gross Profit | $39,493 | $36,679 | $19,157 | $7,680 |
| % Margin | 86.1% | 96.6% | 95.6% | 100% |
| EBITDA | -$57,700 | -$63,989 | -$83,757 | -$89,363 |
| % Margin | -125.8% | -168.6% | -417.9% | -1,163.6% |
| Net Income | -$60,715 | -$71,847 | -$84,846 | -$94,169 |
| % Margin | -132.4% | -189.3% | -423.3% | -1,226.2% |
| EPS Diluted | -0.7 | -0.83 | -0.99 | -1.1 |
| % Growth | 15.7% | 16.2% | 10% | – |
| Operating Cash Flow | -$70,535 | -$87,795 | -$95,162 | -$57,388 |
| Capital Expenditures | -$131 | $0 | $0 | $0 |
| Free Cash Flow | -$70,666 | -$87,795 | -$95,162 | -$57,388 |